The price of Kenvue Inc (NYSE:KVUE) shares last traded on Wall Street fell -1.07% to $21.23.
KVUE stock price is now 5.90% away from the 50-day moving average and -1.15% away from the 200-day moving average. The market capitalization of the company currently stands at $40.65B.
On November 17, 2023, Piper Sandler recently initiated its ‘Neutral’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, ALLISON RICHARD E JR, Director bought 5,598 shares of the company’s stock on Aug 30 ’23. The stock was bought for $128,524 at an average price of $22.96. Upon completion of the transaction, the Director now directly owns 25,598 shares in the company, valued at $0.54 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 11 ’23, Director ALLISON RICHARD E JR bought 20,000 shares of the business’s stock. A total of $525,232 was incurred on buying the stock at an average price of $26.26. This leaves the insider owning 20,000 shares of the company worth $0.42 million. A total of 19.13% of the company’s stock is owned by insiders.
During the past 12 months, Kenvue Inc has had a low of $17.82 and a high of $27.80. As of last week, the company has a debt-to-equity ratio of 0.75, a current ratio of 1.12, and a quick ratio of 0.78. The fifty day moving average price for KVUE is $20.05 and a two-hundred day moving average price translates $21.48 for the stock.
The latest earnings results from Kenvue Inc (NYSE: KVUE) was released for Dec, 2023. According to the Household & Personal Products Company, earnings per share came in at $0.31, beating analysts’ expectations of $0.28 by 0.03. This compares to $0.20 EPS in the same period last year. The net profit margin was 9.88% and return on equity was 9.77% for KVUE. The company reported revenue of $3.67 billion for the quarter, compared to $3.77 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.68 percent. For the current quarter, analysts expect KVUE to generate $3.8B in revenue.
Kenvue Inc(KVUE) Company Profile
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.
